AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell

Cancer Biology and Therapy

Volumn 16, Issue 1, 2015, Pages 77-87

  Han, Gang ^a   Gong, Hangjun ^a   Wang, Yidong ^a   Guo, Shaowen ^a   Liu, Kun ^a  

^a SHUGUANG HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

AMPK; apoptosis; gastric cancer; metformin; mTOR; survivin

Indexed keywords

ADENYLATE KINASE; BACULOVIRAL IAP REPEAT CONTAINING PROTEIN 5; CASPASE 3; CASPASE 7; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEINASE INHIBITOR; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INHIBITOR OF APOPTOSIS PROTEIN; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BGC-823 CELL LINE; CANCER INHIBITION; CANCER THERAPY; CASPASE ASSAY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GASTRIC CANCER CELL LINE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MKN28 CELL LINE; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; SGC-7901 CELL LINE; STOMACH CANCER; STOMACH CARCINOGENESIS; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; STOMACH TUMOR; TUMOR CELL LINE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; METFORMIN; MICE; PHOSPHORYLATION; RNA INTERFERENCE; STOMACH NEOPLASMS; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938588699     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/15384047.2014.987021     Document Type: Article

References (33)

1. Smith JK, McPhee JT, Hill JS, Whalen GF, Sullivan ME, Litwin DE, Anderson FA, Tseng JF. National outcomes after gastric resection for neoplasm. Archives of Surgery 2007; 142:387-93; PMID:17441293; http://dx.doi.org/10.1001/archsurg.142.4.387
2. Lordick F, Siewert JR. Recent advances in multimodal treatment for gastric cancer: a review. Gastric Cancer 2005; 8:78-85; PMID:15864714; http://dx.doi.org/10.1007/s10120-005-0321-z
3. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes care 2010; 33:S11-S61; PMID:20042772; http://dx.doi.org/10.2337/dc10-S011
4. Brown KA, Hunger NI, Docanto M, Simpson ER. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Res Treat 2010; 123:591-6; PMID:20300828; http://dx.doi.org/10.1007/s10549-010-0834-y
5. Zhou XZ, Xue YM, Zhu B, Sha JP. Effects of metformin on proliferation of human colon carcinoma cell line SW-480. J Southern Med University 2010; 30:1935-8, 42; PMID:20813708
6. Sahra IB, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y, Bost F. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27:3576-86; PMID:18212742; http://dx.doi.org/10.1038/sj.onc.1211024
7. Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac-Dumanovic M, Starcevic V, Micic D, Trajkovic V. Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci 2007; 64:1290-302; PMID:17447005; http://dx.doi.org/10.1007/s00018-007-7080-4
8. Ko EM, Walter P, Jackson A, Clark L, Franasiak J, Bolac C, Havrilesky LJ, Secord AA, Moore DT, Gehrig PA, et al. Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol 2014; 132:438-42; PMID: 24269517; http://dx.doi.org/10.1016/j.ygyno.2013.11.021.
9. DeCensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prevention Res 2010; 3:1451-61; PMID:20947488; http://dx.doi.org/10.1158/1940-6207.CAPR-10-0157
10. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. CA 2010; 60:207-21; PMID:20554718
11. Jalving M, Gietema JA, Lefrandt JD, Jong Sd, Reyners AKL, Gans ROB, de Vries EG. Metformin: taking away the candy for cancer? Eur J Cancer 2010; 46:2369-80; PMID:20656475; http://dx.doi.org/10.1016/j.ejca.2010.06.012
12. Kim I, Xu W, Reed JC. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Disco 2008; 7:1013-30; PMID:19043451; http://dx.doi.org/10.1038/nrd2755
13. Fulda S. Targeting apoptosis for anticancer therapy. Semin Cancer Biol 2014; pii: S1044-579X(14):00071-6; PMID:24859747; http://dx.doi.org/10.1016/j.semcancer.2014.05.002. [Epub ahead of print]
14. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
15. Athanasoula K, Gogas H, Polonifi K, Vaiopoulos AG, Polyzos A, Mantzourani M. Survivin beyond physiology: orchestration of multistep carcinogenesis and therapeutic potentials. Cancer Lett 2014; 347:175-82; PMID:24560928; http://dx.doi.org/10.1016/j.canlet.2014.02.014
16. Asanuma K, Tsuji N, Endoh T, Yagihashi A, Watanabe N. Survivin enhances Fas ligand expression via up-regulation of specificity protein 1-mediated gene transcription in colon cancer cells. J Immunol 2004; 172:3922-9; PMID:15004200; http://dx.doi.org/10.4049/jimmunol.172.6.3922
17. Endoh T, Tsuji N, Asanuma K, Yagihashi A, Watanabe N. Survivin enhances telomerase activity via up-regulation of specificity protein 1- and c-Myc-mediated human telomerase reverse transcriptase gene transcription. Exp Cell Res 2005; 305:300-11; PMID:15817155; http://dx.doi.org/10.1016/j.yexcr.2004.12.014
18. Kim EK, Miller I, Aja S, Landree LE, Pinn M, McFadden J, Kuhajda FP, Moran TH, Ronnett GV. C75, a fatty acid synthase inhibitor, reduces food intake via hypothalamic AMP-activated protein kinase. J Biol Chem 2004; 279:19970-6; PMID:15028725; http://dx.doi.org/10.1074/jbc.M402165200
19. Deng XS, Wang S, Deng A, Liu B, Edgerton SM, Lind SE, Wahdan-Alaswad R, Thor AD. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle 2012; 11:367-76; PMID:22189713; http://dx.doi.org/10.4161/cc.11.2.18813
20. Feng Y, Ke C, Tang Q, Dong H, Zheng X, Lin W, Ke J, Huang J, Yeung SC, Zhang H. Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell Death Dis 2014; 5:e1088; http://dx.doi.org/10.1038/cddis.2014.59
21. Kato K, Gong J, Iwama H, Kitanaka A, Tani J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, et al. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther 2012; 11:549-60; PMID:22222629; http://dx.doi.org/10.1158/1535-7163.MCT-11-0594
22. An D, Kewalramani G, Chan JK, Qi D, Ghosh S, Pulinilkunnil T, Abrahani A, Innis SM, Rodrigues B. Metformin influences cardiomyocyte cell death by pathways that are dependent and independent of caspase-3. Diabetologia 2006; 49:2174-84; PMID:16868748; http://dx.doi.org/10.1007/s00125-006-0338-9
23. Detaille D, Guigas B, Chauvin C, Batandier C, Fontaine E, Wiernsperger N, Leverve X. Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes 2005; 54:2179-87; PMID:15983220; http://dx.doi.org/10.2337/diabetes.54.7.2179
24. Vazquez-Martin A, Oliveras-Ferraros C, del Barco S, Martin-Castillo B, Menendez JA. The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy. Ann Oncol 2009; 20:592-5; PMID:19153119; http://dx.doi.org/10.1093/annonc/mdn758
25. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012; 122:253-70; PMID:22117616
26. Jin Q, Feng L, Behrens C, Bekele BN, Wistuba, II, Hong WK, Lee HY. Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Res 2007; 67:11630-9; PMID:18089792; http://dx.doi.org/10.1158/0008-5472.CAN-07-2401
27. Hawley SA, Gadalla AE, Olsen GS, Hardie DG. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 2002; 51:2420-5; PMID:12145153; http://dx.doi.org/10.2337/diabetes.51.8.2420
28. Guigas B, Bertrand L, Taleux N, Foretz M, Wiernsperger N, Vertommen D, Andreelli F, Viollet B, Hue L. 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside and metformin inhibit hepatic glucose phosphorylation by an AMP-activated protein kinase-independent effect on glucokinase translocation. Diabetes 2006; 55:865-74; PMID:16567505; http://dx.doi.org/10.2337/diabetes.55.04.06.db05-1178.
29. Vincent EE, Coelho PP, Blagih J, Griss T, Viollet B, Jones RG. Differential effects of AMPK agonists on cell growth and metabolism. Oncogene 2014; PMID: 25241895; http://dx.doi.org/10.1038/onc.2014.301. [Epub ahead of print]
30. Sambol NC, Brookes LG, Chiang J, Goodman AM, Lin ET, Liu CY, Benet LZ. Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man. Br J Clin Pharmacol 1996; 42:510-2; PMID:8904626; http://dx.doi.org/10.1111/j.1365-2125.1996.tb00017.x
31. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y, Bost F. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27:3576-86; PMID:18212742; http://dx.doi.org/10.1038/sj.onc.1211024
32. Wu S, Tan M, Hu Y, Wang JL, Scheuner D, Kaufman RJ. Ultraviolet light activates NFkappaB through translational inhibition of IkappaBalpha synthesis. J Biol Chem 2004; 279:34898-902; PMID:15184376; http://dx.doi.org/10.1074/jbc.M405616200
33. Carrasco RA, Stamm NB, Marcusson E, Sandusky G, Iversen P, Patel BK. Antisense inhibition of survivin expression as a cancer therapeutic. Mol Cancer Ther 2011; 10:221-32; PMID:21216939; http://dx.doi.org/10.1158/1535-7163.MCT-10-0756